Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer
European Journal of Nuclear Medicine and Molecular Imaging · 2024
DOI: 10.1007/s00259-024-06844-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Hartmut Rauch und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, TUM School of Medicine and Health, University Hospital Klinikum Rechts Der Isar, and Central Institute for Translatio…. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Octreotide, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Klinikum rechts der Isar der Technischen Universität München.
Abstract (Originalsprache)
Purpose
Small cell lung cancer (SCLC) is a highly aggressive tumor with neuroendocrine origin. Although SCLC frequently express somatostatin receptor type 2 (SSTR2), a significant clinical benefit of SSTR2-targeted radionuclide therapies of SCLC was not observed so far. We hypothesize that combination treatment with a PARP inhibitor (PARPi) could lead to radiosensitization and increase the effectiveness of SSTR2-targeted therapy in SCLC.
Methods
SSTR2-ligand uptake of the SCLC cell lines H69 and H446 was evaluated in vitro using flow cytometry, and in vivo using SPECT imaging and cut-and-count biodistribution. Single-agent (Olaparib, Rucaparib, [ 177 Lu]Lu-DOTA-TOC) and combination treatment responses were determined in vitro via cell viability, clonogenic survival and γH2AX DNA damage assays. In vivo, we treated athymic nude mice bearing H69 or H446 xenografts with Olaparib, Rucaparib, or [ 177 Lu]Lu-DOTA-TOC alone or with combination treatment regimens to assess the impact on tumor growth and survival of the treated mice.
Results
H446 and H69 cells exhibited low SSTR2 expression, i.e. 60 to 90% lower uptake of SSTR2-ligands compared to AR42J cells. In vitro, combination treatment of [ 177 Lu]Lu-DOTA-TOC with PARPi resulted in 2.9- to 67-fold increased potency relative to [ 177 Lu]Lu-DOTA-TOC alone. We observed decreased clonogenic survival and higher amounts of persistent DNA damage compared to single-agent treatment for both Olaparib and Rucaparib. In vivo, tumor doubling times increased to 1.6-fold (H446) and 2.2-fold (H69) under combination treatment, and 1.0 to 1.1-fold (H446) and 1.1 to 1.7-fold (H69) in monotherapies compared to untreated animals. Concurrently, median survival was higher in the combination treatment groups in both models compared to monotherapy and untreated mice. Fractionating the PRRT dose did not lead to further improvement of therapeutic outcome.
Conclusion
The addition of PARPi can markedly improve the potency of SSTR2-targeted PRRT in SCLC models in SSTR2 low-expressing tumors. Further evaluation in humans seems justified based on the results as novel treatment options for SCLC are urgently needed. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, TUM School of Medicine and Health, University Hospital Klinikum Rechts Der Isar, and Central Institute for Translational Cancer Research (TranslaTUM), Technical University of Munich, Muni…
- Comparative Experimental Pathology (CEP), Institute of Pathology, School of Medicine and Health, Technical University of Munich, Munich, Germany.
- Department of Chemistry, TUM School of Natural Sciences, Technical University Munich, Munich, Germany. s.kossatz@tum.de.
ORCID-Profile: Hartmut Rauch, Carolin Kitzberger, Kirti Janghu, Pavithra Hawarihewa, Nghia T Nguyen, Simone Ballke, Katja Steiger, Wolfgang A Weber, Susanne Kossatz
Förderung
- Klinikum rechts der Isar der Technischen Universität München
Zitieren
APA
Rauch, H., Kitzberger, C., Janghu, K., Hawarihewa, P., Nguyen, N. T., Min, Y., Ballke, S., Steiger, K., Weber, W. A., & Kossatz, S. (2024). Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06844-1
Vancouver
Rauch H, Kitzberger C, Janghu K, Hawarihewa P, Nguyen NT, Min Y, et al. Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06844-1
BibTeX
@article{Rauch2024,
author = {Rauch, Hartmut and Kitzberger, Carolin and Janghu, Kirti and Hawarihewa, Pavithra and Nguyen, Nghia T and Min, Yu and Ballke, Simone and Steiger, Katja and Weber, Wolfgang A and Kossatz, Susanne},
title = {Combining [177Lu]Lu-DOTA-TOC PRRT with PARP inhibitors to enhance treatment efficacy in small cell lung cancer},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2024},
doi = {10.1007/s00259-024-06844-1}
}
EUVIMED